Page 6 - Ndpoint Threat Detection And Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ndpoint threat detection and response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ndpoint Threat Detection And Response Today - Breaking & Trending Today

Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren's Syndrome

Only Sjögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types

Patients with moderate-to-severe systemic disease activity treated with. | May 31, 2023 ....

South Hall , Argyll And Bute , United Kingdom , Elizabethhz Thompson , Newcastle University , European Congress , Company Phase , Clinical Research Institute , Horizon Therapeutics , Moderate To Severe Systemic Disease , Syndrome Disease Activity Index , Concept Study , Session Room , Syndrome Patient Reported Index , Biomarker Analysis , Reduces Blood Biomarkers , Poster Hall , Syndrome Trial , Horizon Therapeutics Public Limited Company Stock Exchange , Press Release , Reated Hznp Ie00bqpvqz61 ,

RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

Company to Present Interim Analysis Secondary Endpoint Data Including Progression-free Survival from Phase III TIGeR-PaC Study, a Multi-center Open-label Study Evaluating RenovoGem™ to Treat. | May 25, 2023 ....

United States , Comunidad Autonoma De Cataluna , Michaelj Pishvaian , Michael Jon Pishvaian , Shaun Bagai , Company Nasdaq , Securities Exchange , World Congress On Gastrointestinal Cancer , Clinical Research Programs , American Association Of Clinical Research , Exchange Commission , Renovorx Inc , John Hopkins School Of Public Health , Gastrointestinal Cancer , American Association , Clinical Research , Principal Investigator , Drug Applications , Targeted Intra Arterial Gemcitabine , Locally Advanced Pancreatic Cancer , Developmental Therapeutics , Associate Professor , John Hopkins School , Public Health , Trans Arterial Micro Perfusion , Securities Act ,

Transforming clinical trial endpoint analysis: Clario implements over 30 AI solutions to deliver faster and accurate results

AI and ML solutions are enhancing Clario's scientists' abilities to deliver a more efficient, accurate and faster analysis of trial participant data collection. These novel tools optimize operations ....

United States , Todd Rudo , Gewinn Nur , Prnewswire Clario , Duncan Cantor , Artificial Intelligence , Machine Learning , Chief Medical Officer , Cardiac Safety , Precision Motion , Achim Sch , Innovation Officer ,

Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma

– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months. | May 22, 2023 ....

United States , Jordyn Temperato , Avanish Vellanki , Drug Administration , Globenewswire Inc , Exchange Commission , Lifesci Communications , Rain Oncology Inc , Data Results , Orphan Drug Designation , Private Securities Litigation Reform Act , Annual Report , Rain Oncology Inc Stock Exchange , Press Release , Ersus Rain Us75082q1058 ,

MicroPort Scientific : ®'s LAA Closure AnchorMan® Device Achieves Primary Endpoint from SAFE PROTECT Clinical Trial, Showing Very Promising Results.

Paris, France, May 17, 2023 - Today, MicroPort® announced primary endpoint data at 12 months from the SAFE PROTECT clinical trial. The results of the SAFE PROTECT trial demonstrated that. | May 17, 2023 ....

France General , United States , Microport Cardioadvent , National Medical Products Administration , Boston Scientific , Microport Scientific Corporation The Group , Microport Scientific Corporation , Left Atrial Appendage Closure , Shanghai Chest Hospital , Port Scientific Corporation , Diabetes Care , Endocrinal Management , Microport Scientific , Microport Scientific Corporation Stock Exchange , Press Release , Emonstrated 853 Kyg608371046 ,